MedTrace Logo

Study on the Body Mass Balance and Biotransformation of [14C]-HEC585

NCT05468346 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-04-13

No results posted yet for this study

Summary

This is a single-centre, open-label, non-randomised, single-dose study in healthy male subjects designed to assess the mass balance and biotransformation of \[14C\]-HEC-585.

Conditions

  • Healthy Volunteer

Interventions

DRUG

[14C]-HEC585

Single Dose = Solution containing 200 mg/100 µCi \[14C\]-HEC585

Sponsors & Collaborators

  • Sunshine Lake Pharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-26
Primary Completion
2022-08-14
Completion
2022-08-29
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05468346 on ClinicalTrials.gov